These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Maury P; Baratto F; Zeppenfeld K; Klein G; Delacretaz E; Sacher F; Pruvot E; Brigadeau F; Rollin A; Andronache M; Maccabelli G; Gawrysiak M; Brenner R; Forclaz A; Schlaepfer J; Lacroix D; Duparc A; Mondoly P; Bouisset F; Delay M; Hocini M; Derval N; Sadoul N; Magnin-Poull I; Klug D; Haïssaguerre M; Jaïs P; Della Bella P; De Chillou C Eur Heart J; 2014 Jun; 35(22):1479-85. PubMed ID: 24536081 [TBL] [Abstract][Full Text] [Related]
66. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention. Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305 [TBL] [Abstract][Full Text] [Related]
67. Interventions to decrease the morbidity and mortality associated with implantable cardioverter-defibrillator shocks. Bradfield JS; Buch E; Shivkumar K Curr Opin Crit Care; 2012 Oct; 18(5):432-7. PubMed ID: 22889870 [TBL] [Abstract][Full Text] [Related]
68. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Dukkipati SR; d'Avila A; Soejima K; Bala R; Inada K; Singh S; Stevenson WG; Marchlinski FE; Reddy VY Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):185-94. PubMed ID: 21270104 [TBL] [Abstract][Full Text] [Related]
69. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573 [TBL] [Abstract][Full Text] [Related]
70. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378 [TBL] [Abstract][Full Text] [Related]
71. Is the coexistence of sustained ST-segment elevation and abnormal Q waves a risk factor for electrical storm in implanted cardioverter defibrillator patients with structural heart diseases? Furushima H; Chinushi M; Iijima K; Hasegawa K; Sato A; Izumi D; Watanabe H; Aizawa Y Europace; 2012 May; 14(5):675-81. PubMed ID: 22158850 [TBL] [Abstract][Full Text] [Related]
72. Suppression of storms of ventricular tachycardia by epicardial ablation of isolated delayed potential in noncompaction cardiomyopathy. Chinushi M; Iijima K; Furushima H; Izumi D; Sato A; Yagihara N; Hasegawa K; Watanabe H; Soejima K; Aizawa Y Pacing Clin Electrophysiol; 2013 Apr; 36(4):e115-9. PubMed ID: 21208238 [TBL] [Abstract][Full Text] [Related]
73. Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator. Sauer WH; Zado E; Gerstenfeld EP; Marchlinski FE; Callans DJ Heart Rhythm; 2010 Jan; 7(1):9-14. PubMed ID: 19939743 [TBL] [Abstract][Full Text] [Related]
74. Mapping and ablation procedures for the treatment of ventricular tachycardia. Killu AM; Mulpuru SK; Asirvatham SJ Expert Rev Cardiovasc Ther; 2016 Sep; 14(9):1071-87. PubMed ID: 27269734 [TBL] [Abstract][Full Text] [Related]
75. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727 [TBL] [Abstract][Full Text] [Related]
76. Renal Denervation for Ventricular Arrhythmia in Patients with Implantable Cardioverter Defibrillators. Jiang Z; Zhou X; Chen C; Wang Y; Fang P; Geng J; Zhang G; Shan Q Int Heart J; 2018 Mar; 59(2):328-332. PubMed ID: 29479013 [TBL] [Abstract][Full Text] [Related]
77. Advantages of a subcutaneous implantable cardioverter-defibrillator in LAMP2 hypertrophic cardiomyopathy. Zaki A; Zaidi A; Newman WG; Garratt CJ J Cardiovasc Electrophysiol; 2013 Sep; 24(9):1051-3. PubMed ID: 23577876 [TBL] [Abstract][Full Text] [Related]
78. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044 [TBL] [Abstract][Full Text] [Related]
80. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]